Sunday, September 13, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 5, 2026

Human Vaccines Market Size to Reach USD 62.45 Billion by 2033, Driven by Expanding Immunization Programs – SNS Insider

View original at globenewswire.com
Human Vaccines Market Size to Reach USD 62.45 Billion by 2033, Driven by Expanding Immunization Programs – SNS Insider Austin, United States, Feb…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • COVID-19 vaccines dominated with a 31.25% share in 2025

    80% confidence

  • Intradermal delivery is projected to expand at the fastest CAGR of 6.45% during the forecast period

    80% confidence

  • North America dominated the Human Vaccines Market, accounting for a 34.56% market share in 2025

    80% confidence

  • Online Pharmacy is expected to grow at the fastest CAGR of 6.78% during 2026–2033

    80% confidence

  • HPV vaccines are anticipated to record the fastest CAGR of 7.34% through 2026–2033

    80% confidence

  • The Human Vaccines Market size was valued at USD 44.26 billion in 2025 and is expected to reach USD 62.45 billion by 2033, growing at a CAGR of 4.43% during the forecast period of 2026-2033

    80% confidence

  • Hospitals accounted for the largest share of 53.12% in 2025

    80% confidence

  • The Human Vaccines Market is driven by the rising awareness of preventive healthcare, expansion of national immunization programs, and rising cases of infectious and chronic diseases

    80% confidence

  • Hospital Pharmacy held the largest share of 45.87% in 2025

    80% confidence

  • Adult vaccines held the largest share of 39.61% in 2025

    80% confidence

  • Geriatric vaccines are expected to grow at the fastest CAGR of 6.98% during 2026–2033

    80% confidence

  • Inactivated vaccines held the largest market share of 28.74% in 2025

    80% confidence

  • Government vaccination programs are an essential factor in the development of the market

    80% confidence

  • Research & Academic Institutes are forecasted to register the fastest CAGR of 7.21% during 2026–2033

    80% confidence

  • Intramuscular vaccines accounted for the highest market share of 46.32% in 2025

    80% confidence

  • The U.S. Human Vaccines Market is expected to grow from USD 11.72 billion in 2025 to USD 15.17 billion by 2033, registering a CAGR of 3.30% during the forecast period

    80% confidence

  • mRNA vaccines are expected to grow at the fastest CAGR of 7.12% during 2026–2033

    80% confidence

  • The market is challenged by high development costs, complex manufacturing processes, and strict regulatory requirements

    80% confidence

  • The Asia Pacific Human Vaccines Market is the fastest-growing globally, projected to register a CAGR of 5.89% during 2026–2033

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Keeps Flowing as Enterprise Adoption and Government Contracts Validate the Bet
A late-August surge of nine-figure funding rounds (Socure, Stability AI, Generalist AI, Gatik, Regent Craft, Emerald AI, Owner) shows venture capital still pouring into AI infrastructure, identity/fintech, and autonomy, even as public-market sentiment stays jumpy — Palantir's stock fell 6% the same week it landed the Army's TITAN contract. UiPath's raised guidance and strong Q2 results, alongside efficiency breakthroughs like Multiverse Computing's model compression, point to real enterprise monetization catching up to the funding hype.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts record the same attribute (net_income) for JPMorgan Chase & Co. in the identical fiscal period (Q1 2026) and observation date (2026-03-31), but report values that differ by approximately 1 billion times: $16,494,000,000 vs $16.49. These cannot both be true simultaneously. The discrepancy suggests either a unit mismatch (e.g., one is total net income, the other earnings per share mislabeled as net_income), a decimal point error, or data entry corruption. For the same entity, attribute, and time period, only one value can be correct.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,280 source documents archived
Query this data → isubstrate.com
Human Vaccines Market Size to Reach USD 62.45 Billion by 2033, Driven by Expanding Immunization Programs – SNS Insider — Source | Via News | Finance Via News